Coeptis announces Z Squared merger, spins out biotech ops; adds AI marketing unit amid losses

Filed March 19, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 28, 2025 · ~2 min read

Key Changes

• high

  Company signed definitive merger with Z Squared (close expected Q2 2026) and will spin out its entire biotechnology business to existing shareholders beforehand, fundamentally restructuring the asset base.

  Business: Pending merger with Z Squared verify on EDGAR →
• high

  Strategic pivot announced alongside workforce reduction (7 to 6 employees), removed material-weakness disclosure, dramatically shortened risk section, and terminated prior strategic exploration with Vy-Gen—suggesting aspirational rather than executed positioning in AI marketing.

  Business: NexGenAI acquisition + MD&A: Employee count + Risk Factors verify on EDGAR →
• high

  Net loss increased 13% year-over-year to $12.3M (2025 vs $10.9M in 2024); accumulated deficit now $110M. Management extended cash runway estimate from Q2 2025 to Q2 2026, indicating either capital raise or reduced burn rate.

  Risk Factors: Net loss and cash runway verify on EDGAR →